---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-055209"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2023-10-25T23:59:59+00:00"
generated_at: "2026-06-09T10:48:43.728872+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viking Q3 net loss $22.5M; cash $376M; obesity trial fully enrolled

## Summary
- Net loss of $22.5M ($0.23/sh) vs $15.8M in Q3 2022; R&D expenses $18.4M, up from $12.0M.
- Cash & equivalents $376M at Sept 30, 2023, vs $155.5M at Dec 31, 2022 (includes $287.5M public offering).
- Phase 2 VENTURE trial of VK2735 (GLP-1/GIP agonist) for obesity fully enrolled (n=176); results expected 1H24.
- Phase 1 oral VK2735 study ongoing; data expected 1Q24. Phase 2b VOYAGE (VK2809 for NASH) histology results expected 1H24.
- Phase 1b VK0214 for X-ALD enrolling; enrollment completion expected 4Q23.

## SEC filing metadata
- accession: 0000950170-23-055209
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2023-10-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017023055209/0000950170-23-055209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017023055209/vktx-20231025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-055209
- JSON: https://secwatch.observer/filing/0000950170-23-055209.json
- Plain text: https://secwatch.observer/filing/0000950170-23-055209.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.